GH1 and Dravet syndrome: Arguments in favor of therapy include a perceived need for extra height to help DS children feel “normal” in an uncaring world and a suggestion of improvement in general wellbeing.Trials show that at 2 years all 16 enrolled patients with GH therapy were above the 95 percentile for DS children. At 3 years there was no drop in growth velocity.